BASIC SCIENCE RESEARCH PROGRAM
Research projects are integrated under the following themes which are highly interactive and are beyond the conventional boundaries of a given expertise area and truly represent the CPDR paradigm:
- Translational CaP Genomics and Proteomics
- Novel CaP Cell Culture Models
- CaP Molecular Genetics
- Hormonal Mechanisms of CaP
Translational CaP Genomics and Proteomics
Translational research of cancer cell and molecular biology-derived discoveries in the pre-clinical or clinical research setting has been the priority of CPDR since its inception. A highly multi-disciplinary research environment of urologists, cancer cell and molecular biologists, genitourinary pathologists, bioinformatics and medical informatics experts, bio-statisticians, medical technologists and regulatory affairs experts supports the CPDR enterprise. Well-characterized CPDR biospecimens banks, recent discoveries showing consistent gene expression alterations in CaP and development of promising new molecular diagnostic technologies, have provided an optimal setting for CPDR to focus in the translational research areas, where we already have developed expertise or in the areas where new initiatives are needed.
Novel Cell Culture Models of CaP
The Prostate Cell Center was established in the newly-renovated CPDR laboratory at the Department of Surgery, USUHS, in January 2000 and has been very active over the years. The Prostate Cell Center has made major advances in the generation of short-term cultures from primary tumors of prostate cancer patients. (1) Total cell strains generated from primary tumors are 134, (2) the number of cell strains generated from normal tissue from the same patient are 72, (3) five well-characterized telomerase-immortalized human CaP cell lines from the tumor of African American and caucasian CaP patients. These cells are critical to the development and use of in vitro models and for the identification of novel therapeutic targets of prostate cancer.
CaP Molecular Genetics
Since its inception, CPDR-BRP has embraced the goal of defining CaP-specific genetic alterations that characterize the disease onset and/or progression. Genetic alterations that are "critical" in the genesis of CaP or molecular alterations that "consistently associate" with CaP will provide definitive molecular targets for the development of bio-markers and new therapeutic targets. This goal has become increasingly more apparent as most of the frequent gene alterations associated with other common human cancers such as breast cancer, colon cancer or lung cancer, do not seem to play a significant role in CaP.
Defining Androgen Signaling in CaP Onset and Progression
Androgen signaling is extremely important in the life and death of the prostate gland and is believed to play an important role in prostate cancer. Hormonal therapy, the most common treatment strategy for the treatment of metastatic prostate cancer works by inhibiting androgen signaling. Accumulating evidence suggests that alterations of androgen signaling in prostate cancer may involve structural or functional alterations of the critical genes at numerous points in the pathway.
March 20, 2014
Collaborative Summer Training Program for HBCU Undergraduates in Washington, DC
Dr. Shiv Srivastava received an FY07 PCRP Collaborative
Undergraduate HBCU Student Summer Training
Program award to provide foundational cancer research
opportunities for undergraduates at the University of
the District of Columbia (UDC) through the Uniformed
Services University of the Health Sciences (USUHS) –
Center for Prostate Disease Research (CPDR). In this
collaborative effort, Dr. Deepak Kumar served as the Partnering Principal Investigator at UDC. This program allowed
UDC students with limited to no exposure in biomedical research to gain experience in state-of-the-art prostate cancer
Read the full Article in the Congressionally Directed Medical Research Programs (CDMRP) Prostate Cancer Reseach Program Brochure (pg 13).
CPDR April 2015
Distinguished Visiting Professor
Deborah Winn, Ph.D.
Division of Cancer Control and Population Sciences
National Cancer Institute
Presentation: "Waterpipes and Health Effects:
Challenges of Studying Emerging
Date: April 2, 2015
Time: 1100 - 1200
Location: CPDR, Rockville, MD
2nd floor conference room
May 2015 Guest Speaker
CAPTAIN Timothy Donahue, MD
Presentation: "Rising PSA after Treatment for Prostate Cancer"
Date: 7 May 2015
Time: 7-8:30 PM
Location: WRNMMC, America Building, 2nd floor, Room 2525
Contact: COL (ret) Jane Hudak for more information at 301-319-2918 or
(The presentation also may be viewed via video teleconference at the Fort Belvoir Community Hospital. Go to the Oaks Pavilion, 1st floor, Room 332, to participate.)